All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lupus Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.

Brought to you by

Scientific Education Support logo
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2024-02-12T11:09:45.000Z

Visual abstract | Safety and efficacy of telitacicept in patients with SLE: Results from a phase IIb trial

By Kreena Mistry
Feb 12, 2024
Share:
Learning objective: After reading this article, learners will be able to cite key safety and efficacy outcomes of telitacicept in adults with systemic lupus erythematosus.

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Telitacicept is a novel fusion protein that inhibits both B lymphocyte stimulator and a proliferation-inducing ligand in active systemic lupus erythematosus.1 Below, we present a visual abstract summarizing key safety and efficacy outcomes of the phase IIb study (NCT02885610) assessing telitacicept in adult patients with active systemic lupus erythematosus.


  1. Wu D, Li J, Xu D, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. Online ahead of print. DOI: 10.1136/ard-2023-224854

More about...
Systemic lupus erythematosus

Related articles

Add bookmark

How might telitacicept fit into the existing treatment landscape for patients with SLE?

During the Lupus Hub Steering Committee meeting, key opinion leaders gathered to discuss how telitacicept might be integrated into the existing treatment approach...

Dec 1, 2023
Add bookmark

How might telitacicept fit into the existing treatment landscape for patients with SLE?

During the Lupus Hub Steering Committee meeting, key opinion leaders gathered to discuss how telitacicept might...

Dec 1, 2023
Add bookmark

Efficacy and safety of telitacicept in patients with SLE: Results from a phase III trial

This article summarizes the key findings of a phase III trial on the efficacy and safety of telitacicept in patients with SLE.

Jul 19, 2023
Add bookmark

Efficacy and safety of telitacicept in patients with SLE: Results from a phase III trial

This article summarizes the key findings of a phase III trial on the efficacy and safety of telitacicept in...

Jul 19, 2023

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox